# Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic Impairment

> **NCT06425198** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 37 (actual)

## Conditions studied

- Hepatic Impairment
- Healthy Participants

## Interventions

- **DRUG:** BMS-986278

## Key facts

- **NCT ID:** NCT06425198
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-06-10
- **Primary completion:** 2024-12-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2025-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06425198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06425198, "Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic Impairment". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT06425198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*